Compare 908 Devices, Inc. with Similar Stocks
Dashboard
1
The company has declared positive results in Mar'2025 after 2 consecutive negative quarters
- PRE-TAX PROFIT(Q) At USD 2.05 MM has Grown at 131.87%
- NET PROFIT(Q) At USD 1.98 MM has Grown at 131.02%
- DEBTORS TURNOVER RATIO(HY) Highest at 7.03 times
2
Risky - Negative EBITDA
3
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
USD 244 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.82
-14.48%
1.79
Revenue and Profits:
Net Sales:
13 Million
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.32%
0%
-18.32%
6 Months
-2.91%
0%
-2.91%
1 Year
167.09%
0%
167.09%
2 Years
-11.59%
0%
-11.59%
3 Years
-39.37%
0%
-39.37%
4 Years
-58.44%
0%
-58.44%
5 Years
-90.76%
0%
-90.76%
908 Devices, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.55%
EBIT Growth (5y)
-233.06%
EBIT to Interest (avg)
-28.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.77
Sales to Capital Employed (avg)
0.36
Tax Ratio
0.30%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
90.69%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.56
EV to EBIT
-4.25
EV to EBITDA
-5.08
EV to Capital Employed
3.48
EV to Sales
2.04
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-81.87%
ROE (Latest)
-16.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 31 Schemes (34.09%)
Foreign Institutions
Held by 40 Foreign Institutions (7.67%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
13.00
11.80
10.17%
Operating Profit (PBDIT) excl Other Income
0.70
-7.10
109.86%
Interest
0.00
0.00
Exceptional Items
-14.90
-2.60
-473.08%
Consolidate Net Profit
-12.90
-9.80
-31.63%
Operating Profit Margin (Excl OI)
-20.60%
-715.50%
69.49%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 10.17% vs -37.23% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -31.63% vs 49.48% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
59.60
50.20
18.73%
Operating Profit (PBDIT) excl Other Income
-28.40
-40.00
29.00%
Interest
0.00
0.20
-100.00%
Exceptional Items
-43.70
-0.40
-10,825.00%
Consolidate Net Profit
-72.20
-36.40
-98.35%
Operating Profit Margin (Excl OI)
-554.50%
-844.20%
28.97%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 18.73% vs 7.04% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -98.35% vs -8.33% in Dec 2023
About 908 Devices, Inc. 
908 Devices, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






